Article
Foxp3 and CD68 as Potential Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumor
2023-01-18
Abstract excerpt
Immune checkpoint inhibitors (ICI) are currently use in a wide range of tumors, but only 20-40% of patients achieve clinical benefit. Aim of our study was to find predictive biomarkers of ICI treatment. We analyzed by immunohistochemistry various cell subsets, including CD3+ cells, CD8+ cells, CD68+ cells, CD20+ cells, FoxP3+ cells, and molecules as LAG-3, IDO1, TGfβ. Comprehensive genomic profiles were analy...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c8069ab1-64a0-508e-8a32-fce36f751f9f
- DOI
- 10.20944/preprints202301.0325.v1
